Abstract
Senile plaques, a neuropathological hallmark of Alzheimer's disease, consist primarily of insoluble aggregates of ß-amyloid peptide (Aß). A 42-residue peptide (Aß1-42) appears to be the predominant form. In contrast to Aß1-40, Aß1-42 is characterized by its extreme tendency to aggregate into fibers or precipitate. A tailored biotechnological method prevents aggregation of Aß1-42 monomers during its production. The method is based on a protein tail fused to the amino terminus of Aß. This tail leads to a high expression in E. coli, and a histidine affinity tag facilitates purification. Selective cleavage of the fusion tail is performed with cyanogen bromide by immobilizing the fusion protein on a reversed phase chromatography column. Cleavage then occurs only at the methionine positioned at the designed site but not at the methionine contained in the membrane anchor sequence of Aß. Furthermore, immobilization prevents aggregation of cleaved Aß. Elution from the HPLC column and all succeeding purification steps are optimized to preserve Aß1-42 as a monomer. Solutions of monomeric Aß1-42 spontaneously aggregate into fibers within hours. This permits the investigation of the transition of monomers into fibers and the correlation of physico-chemical properties with biological activities. Mutations of Aß1-42 at postion 35 influence the aggregation properties. Wild-type Aß1-42 with methionine at position 35 has similar properties as Aß with a methionine sulfoxide residue. The fiber formation tendency, however, is reduced when position 35 is occupied by a glutamine, serine, leucine, or a glutamic acid residue.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Selkoe, D.J. 1991. The molecular pathology of Alzheimer's disease. Neuron 6: 487–498.
Roher, A.E., Lowenson, J.D., Clarke, S., Woods, A.S., Cotter, R.J., Gowing, E. and Ball, M.J. 1993. ß-Amyloid-(1-42) is the major component of cere-brovascular amyloid deposits: Implication for the pathology of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 90: 10836–10840.
Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A.D., Tjernberg, L.O., Silberring, J., Gandy, S.E., Winblad, B., Greengard, P., Nordstedt, C. and Terenius, L. 1994. Relative abundance of Alzheimer Aß amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. USA 91: 8378–8382.
Suzuki, N., Cheung, T.T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T.E. and Younkin, S.G. 1994. An increased percentage of long amyloid ß protein secreted by familial amyloid ß protein precursor (APP727) mutants. Science 264: 1336–1340.
Jarrett, J.T., Berger, E.P. and Lansbury, P.T. 1993. The carboxy terminus of the ß-amyloid protein is critical for the seeding of amyloid formation: Implication for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693–4697.
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N. and Ihara, Y. 1994. Visualization of Aß42(43) and Aß40 in senile plaques with end-specific Aß monoclonals: Evidence that an initial deposited species is Aß42(43). Neuron 13: 45–53.
Gravina, S.A., Ho, L., Eckman, C.B., Long, K.E., Otvos, L., Younkin, L.H., Suzuki, N. and Younkin, S.L. 1995. Amyloid ß protein (Aß) in Alzheimer's disease brain. J. Biol. Chem. 270: 7013–7016.
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Cotman, C. and Glabe, C. 1992. Assembly and aggregation properties of synthetic Alzheimers A4/ß amyloid peptide analogs. J. Biol. Chem 267: 546–554.
May, P.C., Gitter, B.D., Waters, D.C., Simmons, L.K., Becker, G.W., Small, J.S. and Robinson, P.M. 1992. ß-Amyloid peptide in vitro toxicity: Lot-to-lot variability. Neurobiol. of aging 13: 605–607.
Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R. and Stüber, D. 1988. Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate adsorbent. Bio/Technology 6: 1321–1325.
Stüber, D., Matile, H. and Garotta, G. 1990. System for high-level production in Escherichia coli and rapid purification of recombinant proteins: application to epitope mapping, preparation of antibodies, and structure-function analysis. Immunol. Methods 4: 121–152.
Boulanger, N., Matile, H. and Betschait, B. 1988. Formation of the Circum-sporozoite Protein of Plasmodium falciparum in Anopheles stephensi. Acta Tropica 45: 55–561.
Hochuli, E., Döbeli, H. and Schacher, A. 1987. New metal chelate adsorbent selective for proteins and peptides containing neighbouring histidine residues. J. Chromatogr. 411: 177–184.
Dayhojf, M.O. 1978. Atlas of protein sequences and structure, vol 5: suppl.3. National biomedical research foundation, Washington, D.C.
Klunk, W.E., Xu, C.-J. and Pettegrew, J.W. 1994. NMR identification of the formic acid-modified residue in Alzheimer's amyloid protein. J. Neurochem. 62: 349–354.
Schuck, P. 1994. Simultaneous radial and wavelength analysis with the Optima XL-A analytical centrifuge. Progr. Colloid Polym. Sci. 94: 1–13.
Provencher, S.W. and Glöckner, J. 1981. Estimation of globular protein secondary structure from circular dichroism. Biochemistry 20: 33–37.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Döbeli, H., Draeger, N., Huber, G. et al. A Biotechnological Method Provides Access to Aggregation Competent Monomeric Alzheimer's 1–42 Residue Amyloid Peptide. Nat Biotechnol 13, 988–993 (1995). https://doi.org/10.1038/nbt0995-988
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nbt0995-988
This article is cited by
-
The nickel-chelator dimethylglyoxime inhibits human amyloid beta peptide in vitro aggregation
Scientific Reports (2021)
-
Recombinant amyloid beta-peptide production by coexpression with an affibody ligand
BMC Biotechnology (2008)